The complete remission + partial remission rate of 14 studies (1337 cases) reported in patients with NSCLC after chemotherapy indicated that the patients with high expression of ERCC1 were less sensitive to chemotherapy than those with low expression, with the combined OR of 0.53 (95% CI: 0.30∼0.79; P < 0.01). This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.